EIGER BIOPHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee FORM OF INDENTURE Dated as of [●], 20 Debt SecuritiesIndenture • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 17th, 2016 Company Industry JurisdictionINDENTURE, dated as of [●], 20 , among EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
Eiger BioPharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 17th, 2016 Company Industry JurisdictionEiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
EIGER BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Common Stock Warrant Agreement • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 17th, 2016 Company Industry JurisdictionCOMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
EIGER BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20Warrant Agreement • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 17th, 2016 Company Industry JurisdictionDEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
EIGER BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Preferred Stock Warrant Agreement • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 17th, 2016 Company Industry JurisdictionPREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
LICENSE AGREEMENT between EIGER BIOPHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANYLicense Agreement • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 17th, 2016 Company Industry[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
EIGER BIOPHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJune 17th, 2016 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of April 20, 2016 (the “Execution Date”) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), and Bristol-Myers Squibb Company, a Delaware corporation (the “Investor”).